Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.68 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011789 | 0.88 | RXFP1 (0.69) | RXFP1GRM4POLBCA12CA9 | |
| SCHEMBL4979620 | 0.84 | KDR (0.75) | RXFP1GRM4KDRBRAFFLT1 | |
| SCHEMBL15528848 | 0.81 | RXFP1 (1.00) | RXFP1KDRFLT1 | |
| SCHEMBL6055167 | 0.81 | LMNA (0.70) | GRM4KDRLMNATMPRSS4 | |
| SCHEMBL5223022 | 0.80 | POLB (0.75) | RXFP1KDRPOLBLMNAMAPK1 | |
| SCHEMBL12835410 | 0.78 | GRM4 (0.64) | GRM4KDRPOLBLMNAFLT1 | |
| SCHEMBL9951389 | 0.78 | TMPRSS4 (0.74) | GRM4KDRPOLBLMNATMPRSS4 | |
| SCHEMBL3973967 | 0.77 | KDR (0.66) | GRM4KDRLMNATMPRSS4 | |
| SCHEMBL4024545 | 0.77 | KDR (0.69) | GRM4KDRPOLBFLT1TMPRSS4 | |
| SCHEMBL5665935 | 0.77 | FADS1 (0.66) | GRM4KDRPOLBLMNABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446381-B1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2011-01-05 | — | — | EP | claimed |
| EP-2269988-A2 | Anthranilic acid amides and pharmaceutical use thereof | Novartis AG (CH) | 2011-01-05 | — | — | EP | claimed |
| US-7067543-B2 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | claimed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | claimed |
| EP-1446381-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2004-08-18 | — | — | EP | claimed |
| WO-2003040101-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | claimed |
| EP-2269988-B1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2012-05-23 | — | — | EP | disclosed |
| EP-1446381-B1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269988-A2 | Anthranilic acid amides and pharmaceutical use thereof | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | BOLD GUIDO | 2008-04-10 | — | — | US | disclosed |
| EP-1682181-A2 | COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-7067543-B2 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| EP-1667721-A2 | COMBINATIONS OF A VEGF RECEPTOR INHIBITOR WITH OTHER THERAPEUTIC AGENTS | Novartis AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005027972-A2 | COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005027973-A2 | COMBINATIONS OF A VEGF RECEPTOR INHIBITOR WITH OTHER THERAPEUTIC AGENTS | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1446381-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003040101-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | AFF1, FFAR1, FFAR2 | RXFP1 317/4885GRM4 3803/4885KDR 847/4885 |
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | VEGFA, FLT1, FLT4 | RXFP1 693/4885GRM4 3162/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.